In a deal expected to close earlier this month, Agilent Technologies recently announced it signed a merger agreement with scientific information management company Scientific Software Inc. Financial details of the transaction were not disclosed.
BioPhysics Assay Laboratory (BioPAL) announced in mid-June that the National Center for Research Resources of the National Institutes of Health had awarded the company a Phase I Small Business Innovation Research (SBIR) grant.
A special meeting of Argonaut shareholders in early June formally approved the sale of the company’s assets and consumables and process instrument business to Biotage, a move that strengthens the company’s offerings in medicinal chemistry, thermal synthesis, cleanup and purification systems. Total purchase price amounted to 145 million Swedish krona or about $21.2 million. In all, sales from Argonaut products are expected to add over $18 million in annual sales to Biotage’s bottom line, an increase of roughly 25 percent.
Applied Biosystems Inc. and San Diego-based Invitrogen announced in early June a marketing alliance that will offer a suite of labeling products for proteomics researchers that includes Applied Bio’s ITRAQ and ICAT reagents and Invitrogen’s newly-released metabolomic labeling technology SILAC.
At the recent ASMS Conference on Mass Spectrometry, held in San Antonio, Texas, Ciphergen Biosystems introduced the new Deep Proteome Research Services that bring the company’s Equalizer technology to biomarker discovery and identification.
Although it did not disclose the terms of the transaction, Novasite Pharmaceuticals in mid-June announced the acquisition of Boston, Mass.-based PsyCheNomicS, a drug discovery company focused on diseases of the central nervous system (CNS).
In late May, Enzo Life Sciences, a wholly owned subsidiary of Enzo Biochem, launched a new DNA labeling system aimed at array comparative genomic hybridization (aCGH), a technique that detects alterations in the genome leading to changes in DNA copy number.
In a move that is expected to boost both its GeneChip technology and the assays available for its chips, Affymetrix recently acquired ParAllele BioScience, a privately held, South San Francisco-based company that provides assay technology for comprehensive genetic studies. Initially applied to genotyping, these highly flexible assays have the potential to be used in a broad variety of microarray applications.
Pfizer Inc. in mid-June announced its $1.9 billion acquisition of Vicuron Pharmaceuticals, Inc., a biopharmaceutical company focused on developing anti-infectives. Vicuron’s pipeline includes two drugs — anidulafungin, for fungal infections, and dalbavancin, for Gram-positive infections — that Vicuron expects will reach markets in early 2006.
Lexicon Genetics Inc. and Organon announced in late May a long-term multiphase collaboration that leverages their complementary capabilities to discover, develop, and manufacture novel biotherapeutics. The companies will divide evenly eventual product revenues.
Chromos Molecular Systems Inc. in late May entered into a nonexclusive commercial license agreement with Pfizer Inc. Pfizer may now employ Chromos’s ACE (Artificial Chromosome Expression) System in its own labs to develop cell lines that express proteins. Financial details of the deal were not disclosed.
Elixir Pharmaceuticals recently secured an exclusive license to intellectual property from the regents of the University of California (UC) relating to work done by Dr. Eric Verdin and his research group at the Gladstone Institute of Virology and Immunology with SirT1, a member of the sirtuin class of enzymes, and the HIV transcriptional transactivation protein.
Just five years after it began a project to develop the next generation of supercomputers, IBM announced in early June a joint research effort with Switzerland’s The Ecole Polytechnique Fédérale de Lausanne (EPFL), to begin building a detailed model of the largest and most complex part of the human brain, the neocortex. The project, dubbed “Blue Brain”, will employ the staggering computing capacity of IBM’s eServer Blue Gene supercomputer.
The Blueprint Initiative Asia recently introduced directed data curation services that are designed to deliver to clients defined biomolecular interaction data to facilitate scientific research efforts. These curation services are expected to help scientists identify important biological molecules and complexes, such as drug targets, diagnostic biomarkers, and metabolic processes critical to healthcare.
Waters Corp. and Munich, Germany-based InfoChem GmbH announced last month that Waters would include InfoChem’s reaction search technology based on Chemistry Cartridge in future generations of its eLab Notebook software.
Data pipeline and workflow tools company SciTegic and Tripos Inc. announced in late June that Tripos joined SciTegic’s independent software vendor (ISV) partner program to provide software compatibility between their product lines.